Zobrazeno 81 - 90
of 194
pro vyhledávání: '"Umang Swami"'
Autor:
Meredith N Freeman, Albert Jang, Jason Zhu, Farhad Sanati, Lakshminarayanan Nandagopal, Deepak Ravindranathan, Arpita Desai, Audrey Phone, Roberto Nussenzveig, Ellen Jaeger, Sydney A Caputo, Vadim S Koshkin, Umang Swami, Arnab Basu, Mehmet A Bilen, Neeraj Agarwal, Oliver Sartor, Earle F Burgess, Pedro C Barata
Publikováno v:
The oncologist. 27(3)
Background The outcomes of metastatic hormone-sensitive prostate cancer (mHSPC) have significantly improved through treatment intensification, yet Black representation in those studies is suboptimal. Methods A multi-institutional, retrospective analy
Publikováno v:
Clin Cancer Res
PURPOSE: We report efficacy and safety with extended follow-up, and exploratory biomarker analyses from the phase II CheckMate 275 trial to identify biomarkers of response to nivolumab in platinum-resistant metastatic or unresectable urothelial carci
Autor:
Nicolas Sayegh, Bennet Peterson, Nishita Tripathi, Beverly Chigarira, Haoran Li, Kamal Kant Sahu, Deepika Sirohi, Roberto Nussenzveig, Benjamin L. Maughan, Neeraj Agarwal, Umang Swami
Publikováno v:
Cancer Research. 82:5142-5142
Introduction: Use of upfront chemotherapy or novel hormonal therapy (NHT) in patients (pts) with mCSPC has been approved based on improved outcomes. Baseline clinical and genomic correlates associated with inferior outcomes on intensified therapy wou
Autor:
Nishita Tripathi, Yeonjung Jo, Nicolas Sayegh, Beverly Chigarira, Blake Nordblad, Vinay Mathew Thomas, Benjamin Haaland, Roberto Nussenzveig, Sumati Gupta, Neeraj Agarwal, Umang Swami, Benjamin L. Maughan
Publikováno v:
Cancer Research. 82:5995-5995
Background: Presence of liver metastasis is associated with a poor prognosis in mUC. According to the prognostic model by Sonpavde et. al, post platinum treated mUC pts with liver metastasis had a 50% higher risk of death on immunotherapy compared to
Autor:
Deniz Can Guven, Nicolas Sayegh, Nishita Tripathi, Mustafa Erman, Neeraj Agarwal, Umang Swami
Publikováno v:
Journal of Clinical Oncology. 40:5079-5079
5079 Background: ARASENS and PEACE-1 trials have shown that the addition of NHTs to D + androgen deprivation therapy (ADT) improves overall survival (OS) outcomes in mCSPC. However, whether a true synergism is present with using NHT+ADT+D is unknown
Comparing pretest video genetic education for prostate cancer patients: Do patients need assistance?
Autor:
Samantha Greenberg, Elizabeth Orlando, Morgan Devlin, Sara Low, Amanda Anson, Brock O Neil, Wendy Kohlmann, Bob Wong, Christopher B. Dechet, Alejandro Sanchez, Jonathan David Tward, Skyler B Johnson, Neeraj Agarwal, Manish Kohli, Sumati Gupta, Umang Swami, Benjamin L. Maughan
Publikováno v:
Journal of Clinical Oncology. 40:5061-5061
5061 Background: Expanded germline genetic testing recommendations for individuals with prostate cancer (PCa) have resulted in increased demand for pre-test genetic education. As a result, alternative service delivery models in genetic counseling (GC
Publikováno v:
Eur Urol Oncol
BACKGROUND: No standard of care exists for patients with high-risk biochemical recurrence (BCR) after prostatectomy. OBJECTIVE: To evaluate whether addition of docetaxel to androgen deprivation therapy (ADT) improved progression-free survival (PFS) i
Autor:
Umang Swami, Mohammed M. Milhem
Publikováno v:
Ann Transl Med
Publikováno v:
Cancers, Vol 13, Iss 2187, p 2187 (2021)
Cancers
Cancers
Simple Summary Metastatic prostate cancer is an incurable disease with limited treatment options. Immunotherapy has demonstrated significant success in multiple cancer types but efforts to harness its benefit in prostate cancer have so far largely be
Publikováno v:
Annals of surgical oncology. 28(12)
Although the lifetime risk of melanoma is disproportionately higher in whites, blacks have a poorer overall survival with an absolute survival difference of 25%. Significant progress has been made in melanoma treatment in the past decade; however, th